Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study

被引：0

作者：

Coleman, Robert ^{[1
]}

Oaknin, Ana ^{[2
]}

Pignata, Sandro ^{[3
]}

Denys, Hannelore ^{[4
]}

Colombo, Nicoletta ^{[5
]}

Van Gorp, Toon ^{[6
]}

Konner, Jason ^{[7
]}

Marin, Margarita Romeo ^{[8
]}

Harter, Philipp ^{[9
]}

Murphy, Conleth ^{[10
]}

Esteves, Brooke ^{[11
]}

Method, Michael ^{[11
]}

Lorusso, Domenica ^{[12
]}

Matulonis, Ursula ^{[13
]}

机构：

[1] US Oncol Res, The Woodlands, TX USA

[2] Vall Hebron Inst Oncol, Barcelona, Spain

[3] Ist Nazl Tumori Napoli Fdn G Pascale, Naples, Italy

[4] Ghent Univ Hosp, Ghent, Belgium

[5] European Inst Oncol IRCCS, Milan, Italy

[6] Univ Hosp Leuven, Leuven, Belgium

[7] Mem Sloan Kettering Canc Ctr, New York, NY USA

[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[9] Kliniken Essen Mitte, Essen, Germany

[10] Bon Secours Hosp Cork & Canc Trials, Cork, Ireland

[11] ImmunoGen Inc, Waltham, MA USA

[12] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

[13] Dana Farber Canc Inst, Boston, MA USA

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 176卷

关键词：

D O I：

10.1016/j.ygyno.2023.06.468

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

002

引用

页码：S3 / S3

页数：1

共 50 条

[21] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
O'Malley, David M.
Martin, Lainie P.
Gilbert, Lucy
Vergote, Ignace
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Malek, Karim S.
Gonzalez-Martin, Antonio
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts).
Moore, Kathleen N.
Martin, Lainie P.
Matulonis, Ursula A.
Konner, Jason A.
Seward, Shelly Marie
Bauer, Todd Michael
O'Malley, David M.
Perez, Raymond P.
Jeong, Woondong
Zhou, Yinghui
Kirby, Maurice William
Mohanavelu, Satishkumar
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients
Martin, L. P.
Konner, J.
Moore, K. N.
Seward, S. M.
Matulonis, U. A.
Perez, R. P.
Zhou, Y.
Ponte, J.
Zhao, J.
Ruiz-Soto, R.
Birrer, M. J.
GYNECOLOGIC ONCOLOGY, 2017, 145 : 34 - 34
[24] Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Trial: Mirvetuximab Soravtansine (MIRV) Prolongs Overall Survival vs Investigator's Choice Chemotherapy (IC) in Platinum-Resistant Ovarian Cancer (PROC) with High Folate Receptor-Alpha (FRa) Expression
Hilpert, Felix
Harter, Philipp
Lorusso, Domenica
Konecny, Gottfried. E.
Banerjee, Susana
Colombo, Nicoletta
Wang, Yuemei
Stec, James
Method, Michael
Van Gorp, Toon
Moore, Kathleen
de Gregorio, Nikolaus
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 91 - 91
[25] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.
Moore, Kathleen N.
Matulonis, Ursula A.
O'Malley, David M.
Konner, Jason A.
Martin, Lainie P.
Perez, Raymond P.
Bauer, Todd Michael
Gilbert, Lucy
Seward, Shelly Marie
Oza, Amit M.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Initial safety and activity findings froma phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
Matulonis, U. A.
Moore, K. N.
Martin, L. P.
Vergote, I. B.
Castro, C. M.
Gilbert, L.
Berkenblit, A.
Birrer, M. J.
O'Malley, D. M.
GYNECOLOGIC ONCOLOGY, 2018, 149 : 38 - 38
[28] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
Martin, Lainie P.
Konner, Jason A.
Moore, Kathleen N.
Seward, Shelly M.
Matulonis, Ursula A.
Perez, Raymond P.
Su, Ying
Berkenblit, Anna
Ruiz-Soto, Rodrigo
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 402 - 407
[29] FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Moore, K.
Oza, A.
Colombo, N.
Oaknin, A.
Scambia, G.
Lorusso, D.
Farias-Eisner, R.
Banerjee, S.
Murphy, C.
Tanyi, J.
Hirte, H.
Konner, J.
Lim, P.
Hayes, M. Prasad
Monk, B.
Kim, S.
Wang, J.
Pautier, P.
Vergote, I.
Birrer, M.
ANNALS OF ONCOLOGY, 2019, 30
[30] Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
Moore, Kathleen N.
Martin, Lainie P.
O'Malley, David M.
Matulonis, Ursula A.
Konner, Jason A.
Perez, Raymond P.
Bauer, Todd M.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1112 - +

← 1 2 3 4 5 →